Gastric Cancer and Gastroesophageal junction cancer
Conditions
Interventions
adult patients diagnosed with unresectable advanced or metastatic GC/GEJC and received nivolumab 1L treatment:None
Sponsors
Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1.Patients with histologically or cytologically confirmed of diagnosis of unresectable advanced or metastatic GC/GEJC; 2.Patients newly received nivolumab as 1L treatment between 15 June 2018 and 30 June 2023; 3.Patients were aged = 18 years at date of first administration of nivolumab; 4.Patients with at least one tumor assessment after index date, patients who have died or stopped treatment with nivolumab due to AE and have not been evaluated will still be included.
Exclusion criteria
Exclusion criteria: 1.Patients with primary malignancies other than unresectable advanced or metastatic GC/GEJC; 2.Patients who participate in an interventional clinical trial in or before 1L nivolumab treatment for advanced/metastatic GC/GEJC; 3.Patients with known HER2 status positive; 4.Patients who investigator deems inappropriate for inclusion, for example clinical data was incomplete;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to progression (TTP) in 1L; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR) in 1L;Clinical characteristics and treatment patterns of patieents who received nioolumab in first-line;Duration of response (DOR) in 1L;Overall survival (OS);All immune-related adverse event (irAE) and adverse events (AEs) that lead to nivolumab discontinuat; | — |
Countries
China
Contacts
Public ContactXianglin Yuan
Tongji Hospital, Tongji Medical College ,Huazhong University of Science and Technology
Outcome results
None listed